Johnson & Johnson (JNJ) is Thompson Rubinstein Investment Management Inc. OR’s 9th Largest Position

Thompson Rubinstein Investment Management Inc. OR trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 68,680 shares of the company’s stock after selling 2,070 shares during the quarter. Johnson & Johnson comprises about 3.3% of Thompson Rubinstein Investment Management Inc. OR’s holdings, making the stock its 9th biggest position. Thompson Rubinstein Investment Management Inc. OR’s holdings in Johnson & Johnson were worth $8,863,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Intl Fcstone Inc. raised its position in Johnson & Johnson by 13.3% in the 3rd quarter. Intl Fcstone Inc. now owns 5,311 shares of the company’s stock valued at $734,000 after purchasing an additional 625 shares in the last quarter. Cahaba Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $216,000. BTR Capital Management Inc. raised its position in shares of Johnson & Johnson by 3.7% during the 3rd quarter. BTR Capital Management Inc. now owns 99,668 shares of the company’s stock worth $13,771,000 after acquiring an additional 3,516 shares in the last quarter. Benson Investment Management Company Inc. increased its position in Johnson & Johnson by 4.1% during the third quarter. Benson Investment Management Company Inc. now owns 23,323 shares of the company’s stock worth $3,223,000 after buying an additional 925 shares during the period. Finally, Cibc Bank USA increased its position in Johnson & Johnson by 4.5% during the third quarter. Cibc Bank USA now owns 22,640 shares of the company’s stock worth $3,129,000 after buying an additional 967 shares during the period. Institutional investors and hedge funds own 67.20% of the company’s stock.

Shares of JNJ stock traded up $0.32 during midday trading on Friday, hitting $139.05. The company had a trading volume of 4,742,595 shares, compared to its average volume of 6,081,334. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.99. The company has a market capitalization of $373.06 billion, a P/E ratio of 17.00, a price-to-earnings-growth ratio of 2.40 and a beta of 0.67. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The firm had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same period in the previous year, the business earned $2.06 earnings per share. The company’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Friday, May 24th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.73%. Johnson & Johnson’s payout ratio is 44.01%.

Several research analysts have commented on JNJ shares. Morgan Stanley lifted their price target on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 17th. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Citigroup lifted their price target on Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. BMO Capital Markets lifted their price target on Johnson & Johnson from $154.00 to $157.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $146.90.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) is Thompson Rubinstein Investment Management Inc. OR’s 9th Largest Position” was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/11/thompson-rubinstein-investment-management-inc-or-reduces-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: How Do Mutual Funds Work?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.